Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...
A5329 is a study for people who are infected with both HIV and the Hepatitis C virus (HCV) and have never taken Hepatitis C...
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
We will address our hypothesis using a case-control study design. We plan to leverage the existing biorepository of...
Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...
